Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Labcorp Holdings ( (LH) ) has shared an announcement.
Labcorp Holdings Inc., the Burlington, N.C.-based provider of diagnostic and drug development laboratory services, has expanded its board with the appointment of John H. Sampson, M.D., Ph.D., MHSc, MBA, effective February 9, 2026. Sampson, vice chancellor for health affairs and dean of the University of Colorado Anschutz School of Medicine, brings clinical, research and health system leadership experience in oncology, neuroscience, women’s health and personalized medicine that aligns with Labcorp’s strategic priorities.
The company also named Sampson to its Quality and Compliance Committee, signaling a focus on strengthening clinical rigor and governance across its global operations. His background as a practicing neurosurgeon, member of the National Academy of Medicine and prolific researcher in neurologic disease is expected to bolster Labcorp’s efforts to advance earlier diagnosis, personalized medicine and new therapy development for its worldwide customer base.
The most recent analyst rating on (LH) stock is a Buy with a $319.00 price target. To see the full list of analyst forecasts on Labcorp Holdings stock, see the LH Stock Forecast page.
Spark’s Take on LH Stock
According to Spark, TipRanks’ AI Analyst, LH is a Outperform.
The score is driven primarily by solid financial performance (especially strong cash flow) and a constructive earnings outlook with raised free-cash-flow guidance. Technicals are supportive with price above major moving averages and positive MACD, while valuation (P/E 26.6 and ~1.1% yield) is the main constraint; noted risks include Early Development softness and the expected 2026 PAMA headwind.
To see Spark’s full report on LH stock, click here.
More about Labcorp Holdings
Labcorp Holdings Inc. is a global leader in innovative and comprehensive laboratory services, providing diagnostics and drug development capabilities to doctors, hospitals, pharmaceutical companies, researchers and patients. The company operates in roughly 100 countries, performs more than 700 million tests annually and supported over 75% of U.S. FDA-approved new drugs and therapeutic products in 2024.
Average Trading Volume: 772,436
Technical Sentiment Signal: Buy
Current Market Cap: $22.98B
For an in-depth examination of LH stock, go to TipRanks’ Overview page.